Bloomberg Law
Free Newsletter Sign Up
Bloomberg Law
Free Newsletter Sign Up

Aurobindo Says FDA May Take Action After Plant Inspection

Nov. 10, 2021, 3:43 AM

Aurobindo Pharma Ltd. received a communication from the U.S. FDA classifying the inspection conducted at the API manufacturing facility of its Hyderabad plant as “Official Action Indicated”, according to a stock exchange filing.

  • Co. says it believes that the inspection classification will not impact the continuing commercial supplies to the U.S. market from the facility
  • The inspection was conducted between Aug. 2 and Aug. 12
  • “The company will be engaging with the regulator and is fully committed in resolving the status of this facility at the earliest,” it said in the filing


  • Aurobindo Pharma Ltd. rose 0.74% to 677 ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.